Objective
to test that CYP2C19 genotype guided use of oral P2Y12 inhibitors as compared to conventional clopidogrel therapy reduces ischemic events
Study
open-label, randomised trial
Population
patients with stable CAD or ACS (STEMI and NSTEMI)
Endpoints
composite cardiovascular death, MI, stroke, stent thrombosis and severe recurrent ischemia at 12 months
Conclusion
genotype guided P2Y12 inhibitor therapy in patients with CYP2C19 LOF carriers compared to conventional clopidogrel therapy was not associated with a statistically significant difference in adverse events at 12 months
Pereira et al. JAMA. 2020;324:761-71